Doctors are calling a newly-approved drug a “ revolution” in treating the most common blood-borne infection in the United States. But patient advocates warn how those who need it may not be able to afford it; and noisy protests from Paris to San Francisco are trying to drive the displeasure over the price into the open.
Gilead Sciences said Monday that the Food and Drug Administration rejected two marketing applications for HIV treatments, citing quality control problems at the Foster Citry company’s manufacturing facilities.
The AIDS Healthcare Foundation is spearheading a ballot measure in San Francisco to combat what it calls “predatory pricing” of a new AIDS drug.
The Food and Drug Administration has approved the first drug shown to reduce the risk of HIV infection, a milestone in the 30-year battle against the virus that causes AIDS.
The UC-based California HIV/AIDS Research Program (CHRP) has awarded grants totaling $11.8 million to see if a current HIV drug can be used to prevent the onset of the virus.